<DOC>
	<DOCNO>NCT02237547</DOCNO>
	<brief_summary>Human Umbilical Cord-derived Mesenchymal Stem Cells ( UC-MSC ) Bone Marrow Mononuclear Cells ( BMMC ) patient inject spinal fluid intrathecally inject intravenously ( IV ) safe therapeutic procedure spinal cord injury ( SCI ) patient .</brief_summary>
	<brief_title>Safety Feasibility Study Cell Therapy Treatment Spinal Cord Injury</brief_title>
	<detailed_description>The propose study ass primary safety secondary efficacy endpoint autologous bone marrow mononuclear cell allogeneic human umbilical cord-derived mesenchymal stem cell administer 20 male female subject age 18-50 spinal cord injury . These cell administer intrathecally intravenously multiple time course one month . The primary objective freedom treatment-associated adverse event 3 12 month post-treatment . Secondary objective efficacy baseline , 3 month 12 month quantify base follow : American Spinal Cord Injury Association ( ASIA ) classification Frankel Scale .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<criteria>Men woman age 18 50 Paraplegics quadriplegic complete incomplete spinal cord injury . Willingness undergo bone marrow derive autologous cell therapy . Ability willingness make regular visit hospital follow ups protocol procedure comply medical instruction Traumatic Injury spinal cord complete partial damage Magnetic Resonance Imaging ( MRI ) injury level C4 ASIA impairment scale A C Must proof health insurance country residence . Signed informed consent Pre exist current systemic disease lung , liver ( exception : history uncomplicated hepatitis A ) , gastrointestinal , cardiac , Human Immunodeficiency Virus ( HIV ) History life threaten allergic immunemediated reaction Hemodynamic instability Peripheral muscular dystrophy Lactating pregnant woman Women capable childbearing unwilling use multiple form contraception Alcohol drug abuse /dependence Positive test result hepatitis A Hepatitis B OR C Majortraumatic brain injury psychiatric illness Open injury Active infectious disease Life expectancy less one year due terminal condition Neurodegenerative diseases Primary hematologic diseases Any follow medication discontinue one week prior first stem cell administration throughout course treatment . ( 1 week visit 2 one week visit 12 ) Antibiotics Antifungals Antivirals Blood thinner ( avoid bleeding risk bone marrow aspiration IT procedures ) High dose Vitamin D fish oil ( since might prolong bleed time ) Bone reflect increase risk spinal puncture Hepatic dysfunction Other medical complication contraindicate surgery , include major respiratory complication Participation another clinical trial Coagulopathies Uncorrected coagulopathy baseline period define : International Normalized Ratio ( INR ) &gt; 1.4 ; Partial Thromboplastin Time ( PTT ) &gt; 35 sec ; Platelet Count ( PLT ) &lt; 100,000 . Preinjury history seizure disorder and/or neurological impairment participation ageappropriate pain rating scale would practical possible Subject sign inform consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>spinal cord injury</keyword>
	<keyword>mesenchymal</keyword>
	<keyword>bone marrow</keyword>
	<keyword>mononuclear cell</keyword>
	<keyword>stem cell</keyword>
	<keyword>umbilical cord</keyword>
</DOC>